Literature DB >> 27257280

PIK3CA mutations in meningioma.

Gelareh Zadeh1, Shirin Karimi1, Kenneth D Aldape1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27257280      PMCID： PMC4827051          DOI： 10.1093/neuonc/now029

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  15 in total

1.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

Review 2.  Fractionated radiotherapy for intracranial meningiomas.

Authors:  Vinai Gondi; Wolfgang A Tome; Minesh P Mehta
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

3.  Rare mutation of PIK3CA in meningiomas.

Authors:  Jesse Chung-sean Pang; Nellie Yuk Fei Chung; Norman Hok Ling Chan; Wai Sang Poon; Teresa Thomas; Ho-keung Ng
Journal:  Acta Neuropathol       Date:  2006-02-07       Impact factor: 17.088

4.  WHO grade II and III meningiomas: a study of prognostic factors.

Authors:  Anne Durand; François Labrousse; Anne Jouvet; Luc Bauchet; Michel Kalamaridès; Philippe Menei; Robert Deruty; Jean Jacques Moreau; Michelle Fèvre-Montange; Jacques Guyotat
Journal:  J Neurooncol       Date:  2009-06-27       Impact factor: 4.130

5.  PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.

Authors:  Gary L Gallia; Vikki Rand; I-Mei Siu; Charles G Eberhart; C David James; Suely K N Marie; Sueli M Oba-Shinjo; Carlos G Carlotti; Otavia L Caballero; Andrew J G Simpson; Malcolm V Brock; Pierre P Massion; Benjamin S Carson; Gregory J Riggins
Journal:  Mol Cancer Res       Date:  2006-10       Impact factor: 5.852

Review 6.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

Review 7.  Meningioma.

Authors:  Christine Marosi; Marco Hassler; Karl Roessler; Michele Reni; Milena Sant; Elena Mazza; Charles Vecht
Journal:  Crit Rev Oncol Hematol       Date:  2008-03-14       Impact factor: 6.312

8.  Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.

Authors:  Daniel K Broderick; Chunhui Di; Timothy J Parrett; Yardena R Samuels; Jordan M Cummins; Roger E McLendon; Daniel W Fults; Victor E Velculescu; Darell D Bigner; Hai Yan
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

Review 9.  Genetic/molecular alterations of meningiomas and the signaling pathways targeted.

Authors:  Patrícia Domingues; María González-Tablas; Álvaro Otero; Daniel Pascual; Laura Ruiz; David Miranda; Pablo Sousa; Jesús María Gonçalves; María Celeste Lopes; Alberto Orfao; María Dolores Tabernero
Journal:  Oncotarget       Date:  2015-05-10

10.  EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas.

Authors:  Mateusz Bujko; Paulina Kober; Andrzej Tysarowski; Ewa Matyja; Tomasz Mandat; Wiesław Bonicki; Janusz Aleksander Siedlecki
Journal:  Oncol Lett       Date:  2014-04-07       Impact factor: 2.967
View more
  2 in total

1.  New insights into the genomic landscape of meningiomas identified FGFR3 in a subset of patients with favorable prognoses.

Authors:  Aysha AlSahlawi; Rasha Aljelaify; Malak Abedalthagafi; Amna Magrashi; Mariam AlSaeed; Amal Almutairi; Fatimah Alqubaishi; Abdulellah Alturkistani; Abdullah AlObaid; Mohamed Abouelhoda; Latifa AlMubarak; Nada AlTassan
Journal:  Oncotarget       Date:  2019-09-17

2.  Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment.

Authors:  Sylvain Portet; Rania Naoufal; Gaëlle Tachon; Adrien Simonneau; Anaïs Chalant; Amir Naar; Serge Milin; Benoit Bataille; Lucie Karayan-Tapon
Journal:  Neurooncol Adv       Date:  2019-05-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.